ZURICH (Reuters) - Novartis has signed a licensing deal to hand over its experimental tuberculosis (TB) drugs to the Global Alliance for TB Drug Development, joining a growing Big Pharma retreat from antibiotics.
The TB Alliance deal reflects renewed scrutiny of the Novartis portfolio under new chairman Joerg Reinhardt, who is focusing the Swiss company's research on core areas such as cancer, respiratory drugs, heart failure and dermatology.
11:01 Why Yahoo CEO Marissa Mayer’s $141 Million Payday Is Safe From the Hack Cover-Up13
23:37 Here’s Why Netflix’s Share Price Just Hit a New All-Time High11
21:52 Netflix nears 94 million subscribers 10 years after streaming launch21
22:33 Allergan to pay $15 million over failing to disclose merger talks19